A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia: Culver City, Calif Thursday, April 17, 2025, 15:00 Hrs [IST] ...

The following is a summary of “Health-related quality of life after radical cystectomy for bladder cancer in elderly patients ...

Laparoscopic radical cystectomy (LRC) is a challenging technique, but it has been proposed as an alternative to open radical cystectomy (ORC), which is currently the gold standard treatment for ...

Subjects were randomised to receive Imfinzi along with neoadjuvant chemotherapy before and after cystectomy, or to receive neoadjuvant chemotherapy alone before cystectomy without further ...

The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody Imfinzi (durvalumab) with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as an ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

During a live event, Matthew Galsky, MD discussed neoadjuvant and adjuvant options for a patient case including nivolumab or ...

Although radical cystectomy is an effective treatment for bladder cancer, it can have negative effects on urinary and sexual function. Lane et al. have performed nerve-sparing and reproductive ...

Imfinzi in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by Imfinzi as adjuvant monotherapy ...

Three-stage (group 2) 10 3.68 ± 0.55 Unilateral only 3.4 (MD) NS, baseline vs follow-up; NS group 1 vs 2 OE, prior cystectomy (group 2) 112 Not reported but all <6 cm 19.60 7.9 ± 4.2 Tubal ...

The FDA has approved neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab after radical cystectomy in MIBC.